Muscular Dystrophy and Neuronal Migration Disorder Caused by Mutations in a Glycosyltransferase, POMGnT1  by Yoshida, Aruto et al.
Developmental Cell, Vol. 1, 717–724, November, 2001, Copyright 2001 by Cell Press
Muscular Dystrophy and Neuronal Migration
Disorder Caused by Mutations
in a Glycosyltransferase, POMGnT1
Introduction
Since the discovery of the Duchenne muscular dystro-
phy gene product dystrophin (Hoffman et al., 1987),
many studies have focused on understanding the patho-
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physiology of muscular dystrophies and on developingVolker Straub,5 Beril Talim,6 Thomas Voit,5
therapeutic approaches. Dystroglycan is a componentHaluk Topaloglu,7 Tatsushi Toda,2,8,10
of the dystrophin-glycoprotein-complex (DGC) in skele-and Tamao Endo3,8,10
tal muscle, and it is thought to have a crucial role in1 Central Laboratories for Key Technology
linking the extracellular basal lamina to the cytoskeletalKirin Brewery Co., Ltd.
proteins. Structural defects in the DGC can result inKanazawa-ku, Yokohama 236-0004
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cytoskeleton, and this can lead to various muscular dys-Department of Post-Genomics and Diseases
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from their place of birth to reach their final positionJapan
within the correct cortical layer, a process called cortical3 Department of Glycobiology
histogenesis. Several genes that are thought to functionTokyo Metropolitan Institute of Gerontology
in the migration, and assembly of neurons during thisItabashi-ku, 173-0015
process has been implicated in cortical dysgenesis dis-Japan
orders. These genes include reelin, mdab1, which is4 Research Department
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cephaly) and is seen mainly in Finland (Santavuori et al.,Departments of 6 Pediatric Pathology and
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coma, pallor of the optic discs, retinal hypoplasia, men-Ankara 06100
tal retardation, hydrocephalus, abnormal electroen-Turkey
cephalograms, and myoclonic jerks. All infants with MEB
are floppy with generalized muscle weakness, including
facial and neck muscles, from birth. Muscle biopsies
Summary show dystrophic changes, and brain MRIs reveal pachy-
gyria-type cortical neuronal migration disorder, flat brain-
Muscle-eye-brain disease (MEB) is an autosomal re- stem, and cerebellar hypoplasia (Figure 1). The gene
cessive disorder characterized by congenital muscu- responsible for MEB has been mapped to chromosome
lar dystrophy, ocular abnormalities, and lissencephaly. 1p32-34 (Cormand et al., 1999), but it has not been
Mammalian O-mannosyl glycosylation is a rare type identified and the cause of this disease is not known.
of protein modification that is observed in a limited In eukaryotes, proteins are frequently modified by
number of glycoproteins of brain, nerve, and skeletal O-glycosylation as well as by N-glycosylation. O-glyco-
muscle. Here we isolated a human cDNA for protein sylation occurs at Ser and Thr residues. In yeast and
O-mannose -1,2-N-acetylglucosaminyltransferase fungi, O-glycosylation mainly occurs in the form of
(POMGnT1), which participates in O-mannosyl glycan O-mannosylation (Gemmill and Trimble, 1999). However,
synthesis. We also identified six independent muta- O-mannosylation is rare in mammals, occurring in a lim-
tions of the POMGnT1 gene in six patients with MEB. ited number of glycoproteins of brain, nerve, and skele-
Expression of most frequent mutation revealed a great tal muscle (Endo, 1999). The role of O-mannosylation
loss of the enzymatic activity. These findings suggest is not clear. We demonstrated that sialyl O-mannosyl
glycan is a laminin binding ligand of -dystroglycanthat interference in O-mannosyl glycosylation is a new
(Chiba et al., 1997). It is possible that defects inpathomechanism for muscular dystrophy as well as
O-mannosylation may weaken the laminin binding andneuronal migration disorder.
consequently are responsible for muscular dystrophy
and neuronal migration disorders such MEB. Very re-8 Correspondence: endo@tmig.or.jp (T.E.), toda@clgene.med.osaka-u.
cently, a deletion of a glycosyltransferase-like proteinac.jp (T.T.)
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GlcNAc1-2Man linkages (Endo, 1999). This linkage is
assumed to be catalyzed by a glycosyltransferase,
UDP-N-acetylglucosamine: protein O-mannose 1,2-N-
acetylglucosaminyltransferase (POMGnT1). POMGnT1
catalyzes the transfer of N-acetylglucosamine from
UDP-GlcNAc to O-mannosyl glycoproteins, according
to the following reaction: UDP-GlcNAc  Man-R →
GlcNAc1-2Man-R  UDP in which R is protein.
POMGnT1 activity was recently found in brain homoge-
nates of several mammals (Takahashi et al., 2001). Thus,
characterization of this enzyme might help to elucidate
the biosynthetic pathway of mammalian O-mannosyl
glycans.
It should be noted that GlcNAc1-2Man linkages are
also found in N-glycans, where they are catalyzed by two
enzymes, UDP-N-acetylglucosamine: -3-D-mannoside
-1,2-N-acetylglucosaminyltransferase I (GnT-I) and
UDP-N-acetylglucosamine: -6-D-mannoside -1,2-N-
acetylglucosaminyltransferase II (GnT-II) (Schachter,
1995). However, we found that recombinant GnT-I and
-II, expressed by Saccharomyces cerevisiae, had no
ability to catalyze the GlcNAc1-2Man linkage in O-man-
nosyl glycans (Takahashi et al., 2001).
In this study, we cloned and characterized POMGnT1.
We also found that MEB is caused by mutations in the
POMGnT1 gene. These results provide a molecular ba-
sis for the defects in O-mannosyl glycan synthesis and
suggest that interference in O-mannosyl glycosylation
is a new pathomechanism for muscular dystrophy as
well as neuronal migration disorder.
Results
Cloning of Human POMGnT1
A BLAST search of human cDNA sequences homolo-
gous to human GnT-I (Kumar et al., 1990) uncovered
four human EST clones (accession numbers AA911248,
F11377, W77826, and R20086), whose functions have
not been identified. Further computer-aided retrieval of
contiguous EST clones disclosed a cDNA sequence of
approximately 1.6 kb. Based on this sequence, two
cDNA fragments were amplified from human brain RNA
by RT-PCR. An analysis of the sequences of these cDNA
fragments showed a reading frame of 1.3 kb, whose
predicted amino acid sequence is highly homologousFigure 1. MEB Patient Aged 5 Years
to the C-terminal side of human GnT-I (Kumar et al.,(A) Muscle biopsy. Typical rounding fibers and variation in size with
1990). The remaining 5-region of the cDNA was ampli-endomysial connective tissue proliferation. There is also prominent
fied from human brain cDNA by a modified 5-RACEfatty infiltration. HE  20.
(B) Cranial MRI, axial section. Ventricles are enlarged in the presence method. A 0.8 kb 5-RACE fragment completed the
of cortical atrophy. There is diffuse thickening of the cerebral cortex POMGnT1 open reading frame. The nucleotide se-
from the frontal region to the parieto-occipital areas, denoting quence indicated that POMGnT1 is a 660 amino acid
pachygyria. protein (Figure 2A) with a calculated molecular mass
(C) Cranial MRI, sagittal section. Cerebellar hypoplasia and brain
of 71.5 kDa. A hydrophobicity analysis and secondarystem strophy. Corpus callosum is thin.
structure prediction of the amino acid sequence sug-
gested that human POMGnT1 is a type II membrane
that is markedly underglycosylated (Grewal et al., 2001). protein and the region from Phe38 to Ile58 is a putative
Others found a selective deficiency of highly glyco- transmembrane domain. This topology was similar to
sylated -dystroglycan in Fukuyama-type congenital the topologies of other Golgi glycosyltransferases
muscular dystrophy (FCMD) muscle (Hayashi et al., cloned to date.
2001). These findings suggest that interference in glyco-
sylation is one cause of muscular dystrophies, although Expression and Characterization of Human
the mechanism by which this occurs is unclear. POMGnT1 Protein
A key difference between mammalian and yeast-type A transient expression of POMGnT1 cDNA in HEK293T
cells increased their microsomal POMGnT1 activity forO-mannosyl glycans is that those in mammals have the
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a mannosylpeptide approximately 100-fold (0.12 versus apparently different from that of GnT-I (Kumar et al.,
1990).12.8 pmol/h/g protein). When we sonicated the micro-
somal fraction in a buffer containing 2% Triton X-100,
about 60% of the enzyme still bound to the membrane Phylogenic and Genomic Characters of POMGnT1
tightly (data not shown). These results indicated that the Whereas GnT-I is widely distributed in mammals, in-
cloned cDNA encodes a functional membrane-bound sects, nematodes, and plants (Kumar et al., 1990; Chen
glycosyltransferase, POMGnT1. A soluble form of et al., 1999; Strasser et al., 1999), a BLAST search sug-
POMGnT1 was expressed in HEK293T cells to further gested that POMGnT1 orthologs are restricted to mam-
characterize the enzymatic properties of POMGnT1. mals such as mouse, pig, and cattle. This raises the
HX-sPOMGnT1 consisted of the C-terminal 595 amino possibility that the GlcNAc-containing mammalian type
acids (Ser66-Thr660 in Figure 2A). We also transfected O-mannosylation occurs in mammals and is biologically
HEK293T cells to produce a soluble enzyme, HX-sGnT-I, important for mammals only. Figure 2D shows a phylo-
consisting of the C-terminal 407 amino acids (Ser39- genic tree of known GnT-I proteins, GnT-I homologs,
Asn445 in Figure 2A) of human GnT-I (Kumar et al., 1990) and POMGnT1 proteins. Interestingly, human POMGnT1
to compare with HX-sPOMGnT1. The estimated molecu- was positioned between Caenorhabditis elegans and
lar weights of HX-sPOMGnT1 and HX-sGnT-I were ap- plant GnT-I species, and mammalian GnT-I made an
proximately 76 and 52 kDa. independent cluster. The genomic organization of
HX-sPOMGnT1 exhibited POMGnT1 activity, and its POMGnT1 is significantly different from the single exon
activity increased in proportion to (1) the amount of of the human GnT-I coding region (Yip et al., 1997).
enzyme, (2) the incubation time, (3) the amount of UDP- Based on a draft genomic sequence (AL360086) con-
GlcNAc, and (4) the amount of acceptor mannosylpep- taining human POMGnT1, we performed a genomic PCR
tide. Also, the POMGnT1 activity depended on manga- analysis and concluded that POMGnT1 is divided into
nese ion (data not shown). The Km for mannosylpeptide 22 exons and its coding region starts from exon 2 (Figure
was 1.85 mM, and the Km for UDP-GlcNAc was 0.73 2E). Taken together, these findings imply that a primor-
mM when mannosylpeptide (0.4 mM) was used as an dial gene was duplicated a long time ago.
acceptor. The product synthesized by HX-sPOMGnT1
was identified as described previously (Takahashi et al., The POMGnT1 Gene Is Mutated in MEB
2001). In brief, the product was completely digested by Two UniSTS entries (stSG22112 and stSG3089) sug-
streptococcal -N-acetylhexosaminidase, which gested that the human POMGnT1 gene exists at 1p33-
cleaves the GlcNAc1-2Man linkage. The -eliminated 34, whereas the GnT-I gene exists at 5q35. The 1p33-34
product was found to elute at the same position as the locus is supported by the finding that the clone con-
authentic GlcNAc1-2ManOH by HPAEC-PAD (data not taining human POMGnT1 (AL360086) overlaps with an-
shown). Thus, we concluded that the GlcNAc residue is other clone (AL122001) that contains a DNA segment of
linked to the 2 position of the Man residue on the pep- chromosome 1p31.3-33. We noticed that MEB has been
tide. The substrate specificity of two soluble N-acetyl- also mapped to 1p32-34 (Cormand et al., 1999). After
glucosaminyltransferases is summarized in Figure 2B. the initial mapping of the MEB gene to 1p32-p34, the
Although HX-sPOMGnT1 was able to use a mannosyl- MEB locus has been narrowed to a 1-cM interval includ-
peptide as a substrate, it did not transfer a GlcNAc to ing four microsatellite markers, D1S2134, D1S2677,
either mannose or p-nitrophenyl--D-mannopyrano- D1S2824, and D1S2748, by founder-haplotype mapping
side. These results suggested that POMGnT1 closely (Dubowitz, 1999). We further found that the POMGnT1
recognizes an acceptor structure consisting of mannose gene is located within this small candidate interval for
and peptide. Furthermore, HX-sPOMGnT1 did not show MEB. Since defects of DGC cause muscular dystrophies
any detectable GnT-I activity when M5-PA or M3-PA (Campbell, 1995) and O-mannosyl type glycan is re-
was employed as an acceptor, even though it has a quired for the laminin binding of -dystroglycan in DGC
domain that is highly homologous with a part of human (Chiba et al., 1997), it is possible that mutations in the
GnT-I. In contrast, HX-sGnT-I did not show any substan- POMGnT1 gene are related to MEB.
tial POMGnT1 activity, although it exhibited obvious To test this hypothesis, we screened the whole coding
GnT-I activity for both M5-PA and M3-PA. Thus, we region and the exon/intron flanking sequences of the
concluded that human POMGnT1 is a new N-acetylglu- POMGnT1 gene for mutations in five Turkish patients
cosaminyltransferase that is functionally different from and one French patient with MEB. The parents of each
GnT-I. of these patients were either consanguineous or from
the same village. We identified six independent disease-
causing mutations in these patients (Figure 3A). PatientsNorthern Analysis of Human POMGnT1 mRNA
Northern blot analysis of POMGnT1 showed that a tran- YA and KO carried a G to T substitution in intron 17
homozygously, which altered the conserved GT splicingscript of 2.7 kb was expressed in all 23 normal tissues
tested (Figure 2C and Supplemental Data, Figure S1 donor sequence to TT (Figure 3B). Patient SA carried
an A substitution in intron 17 homozygously, which al-[http://www.developmentalcell.com/cgi/content/full/1/
5/717/DC1]), indicating that human POMGnT1 is consti- tered the conserved GT splicing donor sequence to AT.
RT-PCR analysis of skeletal muscle from patient SAtutively expressed in the body. An additional weaker
band of 3.4 kb was also detected in spinal cord, lymph revealed that this mutation caused read-through of in-
tronic sequences, resulting in introduction of a prema-node, and trachea, suggesting that POMGnT1 has two
transcriptional initiation sites or alternative splicing in ture termination codon. The mutation also caused skip-
ping of the upstream exon 17, resulting in deletion ofthese tissues. The expression pattern of POMGnT1 was
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Figure 2. Characterization of Human POMGnT1
(A) Comparison of alignment of deduced amino acid sequences of human POMGnT1 and GnT-I (Kumar et al., 1990). Letters in outline indicate
amino acids involved in the binding of GnT-I to UDP-GlcNAc and Mn2 ion, and the secondary structures of GnT-I are represented by thick
Muscular Dystrophy Caused by Glycosylation Defect
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Figure 3. Point Mutations in Six Patients with
MEB
(A) Summary of mutations of the POMGnT1
gene in MEB patients.
(B) Patients YA, KO, and SA were homozy-
gous for a G to T or A substitution allele in
intron 17, which causes abnormal splicing.
(C) Patient MK was shown to carry a G1743A
transition allele in exon 19 homozygously,
which represents a missense mutation
(Ser550Asn).
(D) Patient CC was homozygous for a 1 bp
deletion at base1813 in exon 20, which
causes a frameshift and a premature termi-
nation.
(E) Patient TLG is a compound-heterozygote
who carries a C1572G transversion in exon
17 (Pro493Arg) and a 1 bp deletion at base
1970 in exon 21 (frameshift).
42 amino acids (data not shown). Patient MK carried 3D). Furthermore, we found that a French patient, TLG, is
a compound heterozygote who carries a C1572G trans-a G1743A transition in exon 19 homozygously, which
represents a Ser550Asn nonconservative amino acid version in exon 17 (Pro493Arg) and a 1-bp deletion at
base 1970 in exon 21 (frameshift and premature termina-change (Figure 3C). Patient CC had a 1 bp deletion at
base 1813 in exon 20 homozygously, causing a frame- tion at codon 633) (Figure 3E). Each mutation coseg-
regated in each pedigree examined (families SA, MK,shift and a premature termination at codon 633 (Figure
lines under the sequence (U¨nligil et al., 2000). The putative transmembrane domains are boxed. The soluble constructs (Ser66-Thr660 for
POMGnT1, Ser39-Asn445 for GnT-I) are indicated by the arrows.
(B) Acceptor substrate specificity of the soluble form human POMGnT1 and GnT-I.
(C) Northern analysis of POMGnT1 mRNA expression in human tissues. A 32P-labeled POMGnT1-specific probe was hybridized to human
multiple tissue Northern blot (Human MTN). The sizes of RNA marker bands are indicated on the left. The same blots were also probed with
32P-labeled human cDNA fragments of GnT-I and G3PDH (middle and lower panels, respectively).
(D) Phylogenic tree of the GnT-I and POMGnT1 family. The phylogenic tree was constructed by the CLUSTAL W algorithm using amino acid
sequences of human POMGnT1 and other GnT-I-related sequences retrieved from the Entrez protein database.
(E) Comparison of genomic organization in the coding region of human POMGnT1 and GnT-I. The organization of human GnT-I was taken
from a reference (Yip et al., 1997). Filled boxes and open boxes indicate exons in the coding region and the noncoding region, respectively.
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Structural defects in DGC, leading to a loss of linkage
between laminin-2 (merosin) in the extracellular matrix
and actin in the subsarcolemmal cytoskeleton, cause
various muscular dystrophies (Campbell, 1995). In this
study, however, MEB is found to be caused by a defect in
a glycosylation enzyme. MEB clinically resembles FCMD
(Fukuyama et al., 1981) and Walker-Warburg syndrome
(Dobyns et al., 1989), sharing the unusual combination
of muscle, eye, and brain abnormalities. The FCMD gene
has been positionally cloned (Kobayashi et al., 1998).
Although the function of its gene product, fukutin, is
not clear, computer analysis predicts that fukutin is an
enzyme that modifies cell-surface glycoproteins or gly-
colipids (Aravind and Koonin, 1999), having similarity
with the results in the current study. Since O-mannosyl
glycan is required for the binding between -dystrogly-
can and laminin (Chiba et al., 1997), the subsequent
aberrant O-mannosylation may weaken binding and
allow disruption of the sarcolemmal linkage of skeletal
Figure 4. Function of the Mutant POMGnT1 Proteins muscle or abnormal migration of neuronal cells. This is
(A) Western blot analysis of Xpress epitope-tagged mutants ex- consistent with the observation that immunostaining of
pressed in HEK293T cells. Proteins in the membrane fractions were the laminin 2 chain was weaker in MEB muscle (Aura-
fractionated by SDS-PAGE and then detected by an anti-Xpress
nen et al., 2000) and that the dystrophic phenotypesepitope antibody. Molecular weight standards are shown on the left.
were induced by an antibody blocking the muscle(B) The rate of GlcNAc transfer to a mannosyl peptide was measured
-dystroglycan and laminin interaction (Brown et al.,using each of the membrane fractions from each transfectant. Analy-
sis of enzyme activity is described in Experimental Procedures. 1999).
The deduced amino acid sequences of POMGnT1 and
GnT-I are compared in Figure 2A. Although the overallCC, and TLG), and we have not detected these six sub-
identity between them was only 23.2%, a particularlystitutions in any of 246 normal chromosomes (data not
conserved region was observed at amino acids 367–505.shown), indicating that these mutations are pathogenic
The hydrophobicity profile and the predicted secondaryand that the POMGnT1 gene is responsible for MEB.
structure indicated that the conserved regions have a
high structural similarity. The detailed protein structureLoss of Function of the Products from Mutant
of rabbit GnT-I recently reported by U¨nligil et al. (2000)POMGnT1 cDNA
showed that this conserved region corresponds toTo confirm that the mutations observed in patients with
structures from 3 to 8 in domain 1. A disulfide bridge
MEB are responsible for the defects in the synthesis of
connects two  strands (5 and 8) in this region of
O-mannosyl glycan, we examined the function of the
GnT-I, and the corresponding two cysteine residues
expressed mutant cDNAs. Since both read-through of
(Cys421 and Cys490) were also detected in POMGnT1.
intronic sequences and skipping of the upstream exon Thus, the frameworks of the conserved regions in
17 were found in a patient with MEB who carries the POMGnT1 and GnT-I appeared to be very similar. A D/E-
most frequent mutation, we examined two forms of X-D motif, which is flanked by apolar residues, has been
POMGnT1 mRNA that either contained the intron 17 detected in GnT-I as well as several other glycosyltrans-
sequence (intron 17 read-through form) or lack the exon ferases (Chen et al., 1999; U¨nligil et al., 2000). Three
17 sequence (exon 17 skipping form). The enzyme activ- amino acids in the motif and another 13 amino acids of
ity of either POMGnT1 mutant was1% of that of those GnT-I are critical for the binding to UDP-GlcNAc and
expressing the wild-type protein (Figure 4B), despite Mn2 ion (U¨nligil et al., 2000). Ten of 16 residues were
the expression levels of these products being almost detected at the corresponding positions (Arg311,
equivalent (Figure 4A). The estimated molecular weights Asp338, His371, Glu393, Asp395, Leu449, Trp475,
of wild-type, read-through, and exon-skipping were ap- Asp476, Arg480, and Gly502) of human POMGnT1. Inter-
proximately 82, 65, and 78 kDa, respectively. estingly, the putative catalytic base (Asp289) of GnT-I
was conserved at Asp476 in POMGnT1. This high con-
Discussion servation of the catalytic domain suggested that the
catalytic pocket and the reaction mechanism of
In the present study, we have shown that mutations in POMGnT1 are at least partly similar to those of GnT-I.
the POMGnT1 gene, which catalyzes the second gly- On the other hand, POMGnT1 and GnT-I showed
cosyl transfer step in the biosynthesis of mammalian several structural differences. The cytoplasmic tail of
O-mannosyl glycans, are the primary genetic defect in this enzyme was predicted to be the N-terminal 37
MEB and that they are inherited in a loss-of-function amino acids, which is long relative to the cytoplasmic
manner based on identification of the gene mutations tails of other known glycosyltransferases including
and characterization of the gene products. The results GnT-I. More than 110 amino acids of the additional resi-
reported here clearly indicate the importance of the in- dues were found in the putative stem domain of
tact synthesis of O-mannosyl glycans in muscular dys- POMGnT1. In addition, the amino acid sequence from
8 to the C terminus of GnT-I was less conserved introphy as well as neuronal migration disorder.
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into HEK293T cells, and the microsomal fraction of the cells wasPOMGnT1 (Figure 2A). Since the loop following 8 is
obtained.involved in the acceptor binding of GnT-I (U¨nligil et al.,
A soluble form of POMGnT1 tagged with the His-tag and Xpress2000), differences in the region from 8 to the C termini
epitope (HX-sPOMGnT1) was secreted from HEK293T cells by using
may affect the precise specificity of these enzymes for the Ig kappa chain secretion signal. The DNA encoding the secretion
acceptor oligosaccharides. It is interesting that all muta- signal, His-tag, and Xpress epitope was prepared from pSecTag2
A and pcDNA3.1/His C (Invitrogen) by overlap extension PCR. Thetions found in this study occurred from exon 17 to the
DNA was linked to the cDNA encoding Ser66-Thr660 of POMGnT1C terminus of POMGnT1, although the biological signifi-
and introduced into pcDNA3.1 Zeo(). The resulting expressioncance of this remains to be established. As shown in
plasmid was transfected into HEK293T cells as described above.Figure 2C and the Supplemental Figure S1 [http://www.
The culture supernatant was collected after 2 days culture. Similarly,
developmentalcell.com/cgi/content/full/1/5/717/ HX-sGnT-I containing Ser39-Asn445 of human GnT-I (Kumar et al.,
DC1], POMGnT1 expression appears to be mainly con- 1990) was prepared.
The GnT-I activity and the POMGnT1 activity were measured asstitutive in many tissues. This suggests that O-mannosyl
described by Takahashi et al. (2001). Pyridylaminated oligosaccha-glycosylation is strictly regulated by the substrate speci-
ride acceptors, M5-PA and M3-PA, were obtained from Takaraficity of POMGnT1 and/or the expression of an unidenti-
Shuzo (Ohtsu, Japan). The amount of protein was estimated with afied protein O-mannosyltransferase, which transfers a
BCA protein assay reagent kit (Pierce).
mannose to Ser/Thr in proteins. Consequently, a defect
in O-mannosyl glycosylation may lead to the unusual Western and Northern Blot Analyses
combination of muscle, eye, and brain abnormalities. The microsomal fraction of each transfectant was separated on
10% SDS-PAGE and then transferred to a piece of polyvinylideneRecent investigations have revealed that glycosyla-
difluoride membrane. The anti-Xpress epitope (Invitrogen) was usedtion is related to several biological and pathological phe-
as a primary antibody. The reactive protein was visualized usingnomena such as Notch signaling, cancer metastasis,
ECL western blotting detection reagents (Amersham Pharmacia Bio-
and immunity (Dennis et al., 1999; Moloney et al., 2000; tech).
Lowe, 2001). Our findings suggest a new pathomecha- Probe DNA fragments for human POMGnT1, GnT-I, and glyceral-
nism, in which defects of O-mannosyl glycosylation dehyde 3-phosphate dehydrogenase (G3PDH) were labeled with
[-32P]dCTP using a Megaprime DNA labeling system (Amershamcause muscular dystrophies and further neuronal migra-
Pharmacia Biotech). Northern blots of human tissues (Human MTN,tion disorders. A putative glycosyltransferase gene,
MTN II, MTN III; Clontech) were hybridized with a 32P-labeled DNALarge, was recently found to be mutated in the myd
probe in Rapid hybridization buffer (Amersham Pharmacia Biotech)
mouse (Grewal et al., 2001). Others found a selective at 65C.
deficiency of highly glycosylated -dystroglycan in
FCMD muscle (Hayashi et al., 2001). These findings also MEB Patients and Mutation Analysis
Five Turkish and one French linkage-proven MEB families permittedindicate that altered glycosylation is one cause of mus-
analysis of DNA samples. Primers to amplify each exon and sur-cular dystrophies. In either case, however, the type of
rounding intronic sequences were designed from genomic se-change in glycosylation that has occurred remains to
quence of the POMGnT1 gene. PCR products were excised frombe elucidated. It is noteworthy that -dystroglycans in
gels and directly sequenced.
different species and different tissues all have O-manno-
syl glycans. Therefore, O-mannosyl glycan may be im- Construction of Mutant POMGnT1s
portant in the basic function of -dystroglycan, which An expression vector encoding each mutant of POMGnT1 was pre-
pared by site-directed mutagenesis. In brief, we synthesized muta-acts as a linker between the cytoskeleton and the ex-
genic primers, amplified cDNA with mutations from the full-lengthtracellular matrix. Taken together, it is possible that
cDNA clone, and cloned into pcDNA 3.1 Zeo() (Invitrogen). All-dystroglycan is a potential target relevant for disease.
mutant clones were sequenced to confirm the presence of the muta-
Further studies will help us to better understand (1) the tions.
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